Asset Assessment and Clinical Strategy Diligence for BD Decision-Making
- Client needed ongoing assessment of external assets for acquisition or partnership potential.
-
Required a structured view of each asset’s scientific, clinical, strategic, and commercial viability to
inform executive go / no-go decisions.
-
Needed to understand both the quality of the current development approach and the asset’s future value
potential.
-
Conducted end-to-end asset assessments spanning preclinical data, clinical evidence, and development strategy to
identify strengths, risks, and gaps.
-
Developed net-new clinical and evidence-generation strategies to assess future development pathways and value
creation opportunities.
-
Built financial models to size the opportunity, including patient funnel, addressable population, uptake, and ROI
potential.
-
Synthesized scientific, clinical, and commercial findings into an executive-level recommendation on asset
attractiveness.
- Enabled leadership to make more informed acquisition and partnering decisions.
- Identified key risks and value-creation levers across asset development and evidence strategy.
-
Provided an integrated view of clinical potential and commercial upside to support go / no-go investment
decisions.
